Skip to main content

Table 2 Clinical characteristics of the study population based on aspirin regular use

From: Longitudinal analysis of healthy colon establishes aspirin as a suppressor of cancer-related epigenetic aging

Characteristics No. subjects
Time point 1 (t1)a Time point 2 (t2)b
  Nonuserc Long-term user (≥ 2 year)d Nonuserc Long-term user (≥ 2 year)d
  14 (45%) 17 (55%) 11 (35%) 20 (65%)
Age 50–70 (median 50) 51–69 (median 60) 60–77 (median 60) 60–80 (median 70)
BMIe
 Normal (18.5–25) 6 (43%) 10 (59%) 3 (27%) 11 (55%)
 High (≥ 26) 8 (57%) 7 (41%) 8 (73%) 9 (45%)
Polyps
 No Polyps 5 (36%) 13 (76%) 10 (91%) 13 (65%)
 Yes 9 (64%) 4 (24%) 1 (9%) 7 (35%)
  Proximalf 3 (33%) 1 (25%) 0 (0%) 2 (29%)
  Distalg 6 (67%) 3 (35%) 1 (100%) 4 (57%)
  Proximal and distal 0 (0%) 0 (0%) 0 (0%) 1 (14%)
  1. Regular use defined as ≥ 2 tablets/week for ≥ 1 month
  2. aBaseline time point
  3. b10-year follow-up
  4. cNonuser: women who indicated that they did not use the aspirin ≥ 2 tablets/week for ≥ 1 month (“minimum level”)
  5. dLong-term user: women who indicated that they used the aspirin ≥ 2 tablets/week for ≥ 2 years
  6. eBMI: body mass index; height (cm) and weight (kg) were self-reported and BMI was calculated (kg/m2) from these variables
  7. fProximal: cecum
  8. gDistal: sigmoid colon